Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tilrekimig in Moderate-to-Severe Atopic Dermatitis
NCT07765888Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Aug 2026
- Primary completion
- Mar 2028
- Countries
- 2
01
Overview
A Phase 3 trial of tilrekimig in atopic dermatitis (AD), sponsored by Pfizer. Started Aug 2026; status: recruiting.
02
Drugs
tilrekimig
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07765888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07765888.